ESR1 and inflammatory breast carcinoma: Of the 12 patients that were treated, 5 patients had ER−PR−Her2− (triple-negative, TN) IBC subtype; 4 patients had ER−PR−Her2+ IBC; 1 patient had ER+PR−Her2+ IBC; and 2 patients had ER+PR−Her2− IBC at the time of blood collection (Table 1).